

AUTHOR INDEX

Volume 39

January to June 1989

- Adami, H-O, 471
 Aedo, A-R, 275
 Agulnick, A., 687
 Alba, V.M., 519
 Allen, D.S., 179
 Alvarado, G., 519
 Apelo, R., 165
 Armstrong, D., 579
 Arshat, H., 53
 Baird, D.T., 497
 Bajpai, V.K., 563
 Baker, D.A., 119
 Baker, R.F., 245
 Balogh, S., 265, 541
 Baron, P.A., 579
 Barr, K.J., 447
 Basnayake, S., 541
 Bassol, S., 409, 519
 Basu, J., 85
 Batla, A., 431
 Bergman, J., 419
 Bergsjö, P., 471
 Berman, C., 291
 Bernstein, G.S., 95
 Bertolotto, A., 643
 Black, T.R.L., 359
 Buckingham, K.D., 447
 Bulbrook, R.D., 179
 Bygdeman, M., 103
 Canto, T.E., 589
 Cao, R.Q., 569
 Cecchetti, G., 459
 Champion, C.B., 603
 Chatterton, R.T., 291
 Chen, J-k, 385
 Chi, I-C, 507, 603
 Christensen, N.J., 253
 Christoffersen, T., 471
 Clark, G.M.G., 179
 Clark, L.J., 245
 Colven, C.E., 589
 Coulson, A.H., 95
 Cravioto, M.D., 519
 Danforth, D.R., 321
 Darwish, E.A., 619
 David, G.F.X., 299
 DeChetney, A.H., 555
 de la Cruz, D.L., 409
 Dhar, J.D., 563
 Diamond, M.P., 555
 Dominick, R., 507
 El-Habashy, M.A., 619
 Elger, W.A.G., 227
 Enerth, P., 419
 Fakeye, O., 265
 Farley, T.M.M., 471
 Fasoli, M., 459
 Fioretti, P., 643
 Fitzgerald, L.M., 677
 Fotherby, K., 385
 Fruzzetti, F., 643
 Garza-Flores, J., 519
 Gates, D.S., 359
 Giampietro, O., 643
 Gold, J.W.M., 579
 Grubb, G.S., 541
 Gupta, G., 337
 Gupta, S., 307
 Haiba, N.A., 619
 Hammarström, M., 419
 Hanlon, G.W., 205
 He, M-l, 385
 Hernandez, L., 519
 Hill, J.A., 687
 Hodgen, G.D., 321
 Holden, A.E.C., 73
 Indian Council of Medical
 Research Task Force on IUD, 37
 Insler, V., 665
 Ismail, M., 53
 Jackson, R., 653
 Jagan, M.R.P., 227
 Jiang, D.H., 569
 Johannisson, E., 103, 275
 Källén, B., 503
 Kamboj, V.P., 563
 Kanwar, U., 307, 531
 Kapur, M.M., 299
 Kennedy, K.I., 477
 Key, T.J.A., 179
 Klavon, S.L., 541
 Kleinman, D., 665
 Koh, S., 137, 369
 Kumar, A., 275

CONTRACEPTION

- Kumar G., P.531
 Lähteenmäki, P., 73, 195
 Laloraya, M., 531
 Laloraya, M.M., 531
 Lamptey, P., 359
 Landgren, B-M, 275
 LaVecchia, C., 459
 Lavelly, K., 359
 Lavy, G., 555
 Li, H-Y, 331
 Liew, D., 21, 129, 147
 Logan, A.F., 497
 Logan, J., 555
 Lund, E., 471
 Luukkainen, T., 73, 195
 Majumdar, S., 431
 Marriott, C., 205
 Martin, G.P., 205
 McNeilly, A.S., 477
 Meirik, O., 471
 Melis, G., 643
 Miccoli, R., 643
 Mikhail, M., 85
 Milch, P.O., 119
 Minocha, R., 431
 Moore, J.W., 179
 Nakamura, R.M., 95
 Navalesi, R., 643
 Nayel, S.E., 619
 Newton, J.R., 653
 Oberholzer, M., 103
 Orlandi, M.C., 643
 Osteria, T., 165
 Palan, P.R., 85
 Patil, R.K., 227
 Parazzini, F., 459
 Peng, D-R, 331
 Perez-Palacios, G., 519
 Pike, M.C., 179
 Polanco, L.E., 589
 Polsky, B., 579
 Potts, M., 603
 Prasad, R.N.V., 21, 369
 Puertollano, N., 541
 Pulcrano, J., 53
 Puri, C.P., 227
 Rådestad, A., 253
 Rajalakshmi, M., 299
 Ramos, R., 165
 Ramos, R.M., 541
 Ranga, A., 431
 Ratnam, S.S., 21, 129, 137, 147, 155, 369
 Ratsula, K., 73, 187, 195
 Recio, R., 409, 519
 Ricci, C., 643
 Riphagen, F.E., 633
 Rivera, R., 477
 Rivera, R., 519
 Robinson, N., 507
 Rodger, M.W., 497
 Romney, S.L., 85
 Rosenthal, M., 73
 Royston, P., 53
 Said, S.A., 619
 Salvatore, W., 119
 Sanyal, S.N., 307, 431
 Sarov, I., 665
 Segal, S.J., 579
 Sethi, N., 217
 Setty, B.S., 337, 563
 Shain, R.N., 73
 Sharma, R.S., 299
 Sherwin, R.P., 245
 Shi, Y-e, 275
 Singh, K., 129, 137, 147, 155
 Singh, P., 129, 137, 147, 155
 Singh, R.K., 217
 Sitruk, -Ware, R., 1
 Song, B-L, 331
 Song Si, 385
 Spieler, J., 53
 Srivastava, A., 337
 Srivastava, R.K., 217
 Tanphaichitr, N., 677, 687
 Tao, L., 569
 Thorogood, M., 401
 Tilstam, G., 419
 Toivonen, J., 73, 195
 Ueno, H., 579
 Vadigoppula, A.D., 227
 Vera, L., 589
 Vermund, S.H., 85
 Vessey, M., 401
 Viegas, O.A.C., 129, 137, 147, 155
 Vilar, E., 165
 von Schoultz, B., 633
 Walters, N.N., 291
 Wang, D.Y., 179
 Wang, J.M., 569
 Wen, G.Y., 569
 Wiebe, J.P., 447
 Wilkens, L.R., 507, 603
 Wilkins, K.M., 205
 Wu, X.L., 569
 Zhang, Z.R., 569
 Zhou, Q., 569

SUBJECT INDEX

VOLUME 39

January to June 1989

- Abortion induction, effect of RU486 + gemeprost pessary, 497
- Acceptability study,
 - intracervical device releasing levonorgestrel, 73
 - levonorgestrel IUD, 73
 - Norplant(R) implants, 541
 - Nova-T, 73
 - norgestrel, 589
- Androgens, absorption through skin, 1
- Anordiol (2 α ,17 α -diethynyl-A-nor-5 α -androstane-2 β ,17 β -diol),
 - effect on estrous cycle (rat), 291
 - effect on uterus (mouse), 291
- Anti-viral activity, gossypol, 579
- Ascorbic acid levels, effects of smoking and oral
 - contraception, 85
- Bacterial migration, presence of IUCD monofilament tails, 205
- Barrier contraceptive use, effect on ascorbic acid levels, 85
- Benzoic acid derivatives, effect on sperm motility (rat), 531
- Biochemical study, evaluation of styrene maleic anhydride injection into vas deferens (rat), 217
- BIOSELF 110, effectiveness as fertility indicator, 53
- Bleeding pattern,
 - effect of ethinyl estradiol + levonorgestrel, 165
 - effect of ethinyl estradiol + norethindrone, 165
 - effect of levonorgestrel, 541
- Blood-testis barrier, entry of gossypol (rat), 569
- Body weight, effect of gossypol (rat, hamster), 337
- Breast cancer and oral contraceptives, 471
- Breastfeeding,
 - factors related to return of fertility, 477
 - use as family planning method, 477
- Breastfeeding behavior and lactational infertility, 477
- Breastfeeding women,
 - performance of TCu-380Ag, 603
 - use of norgestrel, 589
- Ca++ uptake and Ca++-ATPase in spermatozoa, effect of gossypol, 431
- Ceruloplasmin level,
 - effect of ethinyl oestradiol + levonorgestrel, 385
 - effect of ethinyl oestradiol + norethisterone, 385
 - effect of levonorgestrel, 385

CONTRACEPTION

- Cervical cytology,
 - effect of estradiol cypionate + medroxy-progesterone acetate, 619
 - effect of estradiol valerate + norethisterone enanthate, 619
- Cervical dilatation, effect of magnesium sulphate in Lamicel, 253
- Cervical laceration, incidence and risk factors during IUD insertion, 507
- Cervical mucus, effect of 3-keto-desogestrel, 653
- Chlamydia trachomatis, effect of copper on growth, 665
- Cinnamic acid derivatives, effect on sperm motility (rat), 531
- Clinical performance,
 - estradiol cypionate + medroxyprogesterone acetate, 619
 - estradiol valerate + norethisterone enanthate, 619
 - levonorgestrel-releasing intracervical device, 187
- Clinical trial,
 - ethinyl estradiol + levonorgestrel, 165
 - ethinyl estradiol + norethindrone, 165
 - levonorgestrel IUD and copper devices, 37
- Coagulation factors,
 - effect of ethinyl oestradiol + desogestrel, 369
 - effect of ethinyl oestradiol + levonorgestrel, 369
 - effect of levonorgestrel, 137, 155
- Coagulation inhibitors,
 - effect of ethinyl oestradiol + desogestrel, 369
 - effect of ethinyl oestradiol + levonorgestrel, 369
 - effect of levonorgestrel, 137, 155
- Complications and complaints, vasectomy, 359
- Condoms,
 - effect of mineral oil, 95
 - effect of ozone, 245
- Continuation rate,
 - ethinyl estradiol + levonorgestrel, 165
 - ethinyl estradiol + norethindrone, 165
 - levonorgestrel IUD and copper devices, 37
 - norgestrel, 589
- Contraception in Sweden, 633
- Contraceptive methods,
 - survey of general perceptions, 633
 - survey of use, knowledge and attitudes, 633
- Contraceptive use, survey, 633
- Copper, effect of Chlamydia trachomatis growth, 665
- Copper IUDs, incidence of cervical laceration at insertion, 507
- Coumarins, effect on sperm motility (rat), 531
- CuT 200, effect on prolactin and estradiol levels, 519
- CuT 200B, clinical trial, 37
- CuT 220C, clinical trial, 37
- CuT 380 Ag, clinical trial, 37
- Danazol, use in post-coital contraception, 459

- Discontinuations,
 - copper devices, 37
 - intracervical device releasing levonorgestrel, 73
 - levonorgestrel IUD, 37, 73
 - Nova-T, 73
 - use of estradiol cypionate + medroxyprogesterone acetate, 619
 - use of estradiol valerate + norethisterone enanthate, 619
 - use of norgestrel, 589
- Down syndrome infants, relation to maternal use of oral contraceptives, 503
- Embelin (2,5-dihydroxy-3-undecyl-1,4-benzoquinone), effect on sperm (rat), 307
- Embryo development, effect of norgestrel (mouse), 555
- Endometrial morphology, effect of levonorgestrel, 275
- Endometrium, effect of RU 486, 103
- Epididymis,
 - effect of gossypol (hamster), 337
 - effect of intratesticular glycerol injection (monkey), 447
- Estradiol, absorption through skin, 1
- Estradiol cypionate + medroxyprogesterone acetate,
 - effect on prolactin and estradiol levels, 519
 - metabolic effects, 619
- Estradiol enanthate + dihydroxyprogesterone acetophenide,
 - effect on prolactin and estradiol levels, 519
- Estradiol level,
 - effect of CuT 200, 519
 - effect of estrogen-progesterone injectable contraceptives, 519
 - effect of ethinyl estradiol + norethindrone acetate (monkey), 321
 - effect of 3-keto-desogestrel, 653
 - effect of levonorgestrel, 195, 275
 - effect of ZK 98.299 (monkey), 227
- Estradiol valerate + norethisterone enanthate,
 - effect on prolactin and estradiol levels, 519
 - metabolic effects, 619
- Estro-progestin preparations, use in post-coital contraception, 459
- Estrogen preparations, use in post-coital contraception, 459
- Estrous cycle, effect of anordiol (rat), 291
- Ethinyl estradiol + cyproterone acetate, metabolic effects, 643
- Ethinyl estradiol + desogestrel, metabolic effects, 643
- Ethinyl estradiol + levonorgestrel, clinical study, 155
- Ethinyl estradiol + norethindrone,
 - clinical study, 165
 - effect on natural killer cell activity, 119
- Ethinyl estradiol + norethindrone acetate, study of "Sunday start" method (monkey), 321

CONTRACEPTION

- Ethinyl oestradiol + desogestrel,
 - effect on blood coagulation, fibrinolysis and platelet function, 369
 - metabolic effects, 21
- Ethinyl oestradiol + levonorgestrel,
 - effect on blood coagulation, fibrinolysis and platelet function, 369
 - metabolic effects, 21
- Ethinyl oestradiol + levonorgestrel, effect on SHBG and ceruloplasmin levels, 385
- Ethinyl oestradiol + norethisterone, effect on SHBG and ceruloplasmin levels, 385
- Family planning method, use of breastfeeding, 477
- Fertile and infertile men, seminal fructose levels, 299
- Fertile period analysis, use of BIOSELF 110, 53
- Fertility indicator, BIOSELF 110, 53
- Fertility performance, effect of embelin treatment in males (rat), 307
- Fibrinolytic activity,
 - effect of ethinyl oestradiol + desogestrel, 369
 - effect of ethinyl oestradiol + levonorgestrel, 369
 - effect of levonorgestrel, 137, 155
- Flavonoids, effect on sperm motility (rat), 531
- Follicular diameter, effect of 3-keto-desogestrel, 653
- Fructose levels, semen of fertile and infertile men, 299
- FSH (follicle stimulating hormone)
- FSH level,
 - effect of ethinyl estradiol + norethindrone acetate (monkey), 321
 - effect of glycerol (monkey), 447
 - effect of levonorgestrel, 275
- Gemeprost pessary + RU486, induction of early abortion, 497
- Glucose tolerance,
 - effect of ethinyl estradiol + cyproterone acetate, 643
 - effect of ethinyl estradiol + desogestrel, 643
 - effect of ethinyl estradiol + gestodene, 643
 - effect of ethinyl oestradiol + desogestrel, 21
 - effect of ethinyl oestradiol + levonorgestrel, 21
 - effect of levonorgestrel, 129, 147
- Glycerol intratesticular injection, effect on spermatogenesis (monkey), 447
- Gossypol,
 - effect on body weight and reproductive organ weights (rat, hamster), 337
 - effect on Ca^{++} uptake and Ca^{++} -ATPase in spermatozoa, 431
 - effect on enzymes in sperm plasma membrane vesicles, 431
 - effect on epididymis (hamster), 337
 - effect on human immunodeficiency virus, 579
 - effect on testis (rat, hamster), 337
 - entry across blood-testis barrier (rat), 569

- Gossypol and gossypol analogs,
 effect on sperm motility, 687
 effect on TM4 cell mitochondrial function, 677
- Haematological study, evaluation of styrene maleic anhydride
 injection into vas deferens (rat), 217
- Haemostatic system, effect of levonorgestrel, 137, 155
- hCG level, use of RU486 + gemeprost pessary, 497
- Hemoglobin level, effect of levonorgestrel, 265
- Hormonal methods, post-coital contraception, 459
- Human immunodeficiency virus, effect of gossypol, 579
- Husband's reliability, information on wife's contraceptive
 use, smoking, height and weight, 401
- Implant contraceptive, levonorgestrel, 129, 137, 147, 155,
 265, 541
- Incidence and risk factors, cervical laceration at IUD
 insertion, 507
- Indole derivative, effect on reproduction (guinea pig), 419
- Infertile and fertile men, seminal fructose levels, 299
- Infertile period analysis, use of BIOSELF 110, 53
- Injectable contraceptive,
 estradiol cypionate + medroxyprogesterone
 acetate, 519, 619
 estradiol enanthate + dihydroxyprogesterone
 acetophenide, 519
 estradiol valerate + norethisterone enanthate, 519, 619
- Insertion events, use of TCU-380A in breastfeeding
 women, 603
- Intracervical contraceptive, levonorgestrel-releasing, 73,
 187, 195
- Intratesticular glycerol injection, effect on
 spermatogenesis (monkey), 447
- Intrauterine device (IUCD, IUD),
 CuT 200, 519
 CuT 200B, 37
 CuT 220C, 37
 CuT 380 Ag, 37
 levonorgestrel-releasing, 37, 73
 Nova-T, 73
 TCu-380A, 603
- IUD insertion,
 incidence and risk factors of cervical laceration, 507
 use in post-coital contraception, 459
- IUD use, effect on ascorbic acid levels, 85
- ISO (International Standards Organization)
- ISO Air Burst Test,
 effect of mineral oil on latex condoms, 95
 effect of ozone on latex condoms, 245
- IUCD, IUD (intrauterine contraceptive device)
- IUCD monofilament tails, migration of bacteria, 205
- 3-Keto-desogestrel vaginal ring, pharmacodynamic
 effects, 653
- Lactational amenorrhea, rates and probabilities of
 pregnancy, 477
- Lamical, use in cervical ripening, 253

CONTRACEPTION

- Levonorgestrel,
 - bleeding patterns and acceptability, 541
 - effect on endometrial morphology, 275
 - effect on haemostatic system, 137, 155
 - effect on menstrual pattern, 265
 - effect on metabolic functions, 129, 147
 - effect on ovarian function, 275
 - effect on SHBG and ceruloplasmin levels, 385
- Levonorgestrel IUD,
 - acceptability study, 73
 - clinical trial, 37
- Levonorgestrel level,
 - after administration of levonorgestrel or ethinyl oestradiol + levonorgestrel, 385
 - pharmacokinetic study of levonorgestrel administered in large doses, 275
 - use of intracervical device releasing levonorgestrel, 195
- Levonorgestrel-releasing intracervical device,
 - acceptability study, 73
 - clinical performance, 187
 - effect on ovarian function, 195
- LH (luteinizing hormone)
- LH level,
 - effect of ethinyl estradiol + norethindrone acetate (monkey), 321
 - effect of glycerol (monkey), 447
 - effect of ZK 98.299 (monkey), 227
- Lipid levels,
 - effect of ethinyl oestradiol + desogestrel, 21
 - effect of ethinyl oestradiol + levonorgestrel, 21
- Lipid metabolism,
 - effect of ethinyl estradiol + cyproterone acetate, 643
 - effect of ethinyl estradiol + desogestrel, 643
 - effect of ethinyl estradiol + gestodene, 643
 - effect of levonorgestrel, 129, 147
- Liposomal gossypol formulation, effect on entry across blood-testis barrier (rat), 569
- Liver function, effect of levonorgestrel, 129, 147
- Loop IUDs, incidence of cervical laceration at insertion, 507
- Magnesium sulphate, effect on cervical ripening, 253
- Mechanical methods, post-coital contraception, 459
- Menstrual bleeding pattern, effect of 3-keto-desogestrel, 653
- Menstrual cycle,
 - effect of ethinyl estradiol + norethindrone acetate (monkey), 321
 - effect of ZK 98.299 (monkey), 227
- Menstrual cycle length, effect of levonorgestrel, 275

- Menstrual pattern,
 - effect of estradiol cypionate + medroxyprogesterone acetate, 619
 - effect of estradiol valerate + norethisterone enanthate, 619
 - effect of levonorgestrel, 265, 541
 - levonorgestrel IUD and copper devices, 37
- Metabolic effects,
 - estradiol cypionate + medroxyprogesterone acetate, 619
 - estradiol valerate + norethisterone enanthate, 619
 - ethinyl estradiol + cyproterone acetate, 643
 - ethinyl estradiol + desogestrel, 643
 - ethinyl estradiol + gestodene, 643
 - ethinyl oestradiol + desogestrel, 21
 - ethinyl oestradiol + levonorgestrel, 21
- Metabolic functions, effect of levonorgestrel, 129, 147
- Migration of bacteria, presence of IUCD monofilament tails, 205
- Mineral oil, effect on latex condoms, 95
- Mitochondrial function, effect of gossypol and gossypol analogs, 677
- Mitochondrial proliferation, effect of gossypol and gossypol analogs, 677
- Multiload IUDs, incidence of cervical laceration at insertion, 507
- Natural killer cell activity, effect of ethinyl estradiol + norethindrone, 119
- Nonoxynol-9, soft jelly spermicidal contraceptive capsules, 409
- Norethisterone level, after administration of ethynyl oestradiol + norethisterone, 385
- Norgestrel,
 - effect on development of pre-embryos (mouse), 555
 - use in lactating women, 589
- Norplant(R),
 - bleeding patterns and acceptability, 541
 - effect on haemostatic system, 137
 - effect on menstrual pattern, 265
 - effect on metabolic functions, 129
- Norplant(R)-2,
 - effect on haemostatic system, 155
 - effect on metabolic functions, 147
- Nova-T, acceptability study, 73
- Nulliparous and parous women, risk patterns for breast cancer with oral contraceptive use, 471
- Oestrogen replacement therapy, effect on SHBG concentration, 179
- Oral contraception and smoking, effect on ascorbic acid levels, 85

CONTRACEPTION

- Oral contraceptive,
 - ethinyl estradiol + cyproterone acetate, 643
 - ethinyl estradiol + desogestrel, 643
 - ethinyl estradiol + levonorgestrel, 165
 - ethinyl estradiol + norethindrone, 119, 165
 - ethinyl oestradiol + desogetrel, 21, 369
 - ethinyl oestradiol + levonorgestrel, 21, 369
 - ethynyl oestradiol + levonorgestrel, 385
 - ethynyl oestradiol + norethisterone, 385
 - levonorgestrel, 385
 - norgestrel, 589
 - triphasic ethinyl estradiol + gestodene, 643
 - triphasic ethinyl estradiol + norethindrone acetate (monkey) 321
 - triphasic ethinyl oestradiol + levonorgestrel, 21, 165, 369
- Oral contraceptive use,
 - effect of SHBG concentration, 179
 - relation to Down syndrome infants, 503
 - reliability of surrogate information, 401
- Oral contraceptives and breast cancer, 471
- Ovarian function, effect of levonorgestrel, 195, 275
- Ovarian reaction,
 - effect of 3-keto-desogestrel, 653
 - effect of progestagen-releasing vaginal devices, 653
- Ovulation, during lactational amenorrhea, 477
- Ozone, effect on latex condoms, 245
- Packed cell volume, effect of levonorgestrel, 265
- Parabens, spermicidal activity, 331
- Parous and nulliparous women, risk patterns for breast cancer with oral contraceptive use, 471
- Percutaneous electrocoagulation technique, vasectomy, 359
- PG (prostaglandin)
- Pharmacodynamic effects, 3-keto-desogestrel-releasing vaginal ring, 653
- Platelet function,
 - effect of ethinyl oestradiol + desogestrel, 369
 - effect of ethinyl oestradiol + levonorgestrel, 369
 - effect of levonorgestrel, 137, 155
- Polymer monofilament threads, migration of bacteria, 205
- Polyphenolic compounds, effect on sperm motility (rat), 531
- Polyvinyl alcohol polymer sponge, effect on cervical ripening, 253
- Post-coital contraception,
 - IUD insertion, 459
 - review of published studies, 459
 - use of danazol, 459
 - use of estro-progestins, 459
 - use of high dosage estrogens, 459
- Pregnancy rate and probability, during lactational amenorrhea, 477
- Progesterone, absorption through skin, 1

- Progesterone level,
 - effect of ethinyl estradiol + norethindrone acetate (monkey), 321
 - effect of glycerol (monkey), 447
 - effect of 3-keto-desogestrel, 653
 - effect of levonorgestrel, 195
 - effect of ZK 98.299 (monkey), 227
- Progesterone metabolism, effect of glycerol (monkey), 447
- Prolactin level,
 - effect of CuT 200, 519
 - effect of estrogen-progestogen injectable contraceptives, 519
- Prostaglandin, gemeprost, PGE1 analogue, 497
- Rate-controlled systems, technical approaches, 1
- Removal rate, TCu-380A, 603
- Reproduction, effect of tetrahydrocyclopent-b-indole (guinea pig), 419
- Reproductive organ weights, effect of gossypol (rat, hamster), 337
- Return of fertility, during breastfeeding, 477
- Reverse transcriptase activity, effect of gossypol on human immunodeficiency virus, 579
- Risk factors and incidence, cervical laceration at IUD insertion, 507
- Risk patterns among parous and nulliparous women, breast cancer and contraceptives, 471
- RU486 (Mifepristone), effect of endometrium, 103
- RU486 + gemeprost pessary, induction of early abortion, 497
- Saponins isolated from Sapindus mukorossi, effect on morphology of spermatozoa, 563
- Semen, fructose levels in fertile and infertile men, 299
- SHBG (sex hormone binding globulin)
- SHBG level,
 - effect of ethinyl oestradiol + levonorgestrel, 385
 - effect of ethinyl oestradiol + norethisterone, 385
 - effect of levonorgestrel, 385
 - effect of oestrogen replacement therapy, 179
 - effect of oral contraceptive use, 179
- Side effects,
 - use of ethinyl estradiol + levonorgestrel, 165
 - use of ethinyl estradiol + norethindrone, 165
 - use of norgestrel, 589
 - use of RU486 + gemeprost pessary, 497
- Smoking and oral contraception, effect on ascorbic acid levels, 85
- Sperm concentration, correlated with seminal fructose levels, 299
- Sperm count, effect of intratesticular glycerol injection (monkey), 447
- Sperm morphology, effect of embelin (rat), 307
- Sperm motility,
 - effect of embelin (rat), 307
 - effect of gossypol and gossypol analogs, 687
 - effect of polyphenolic compounds (rat), 531

CONTRACEPTION

- Sperm penetration test, effect of 3-keto-desogestrel, 653
- Sperm plasma membrane vesicles, effect of gossypol on enzymes, 431
- Spermatogenesis, effect of intratesticular glycerol injection (monkey), 447
- Spermatozoa,
 - effect of gossypol, 431
 - effect of saponins isolated from Sapindus mukorossi, 563
- Spermatozoal enzymes, effect of embelin (rat), 307
- Spermicidal activity, parabens, 331
- Spermicidal contraceptive, soft jelly capsules containing nonoxynol-9, 409
- Standard incision and monopolar diathermy technique, vasectomy, 359
- Steroids, transdermal delivery, 1
- Styrene maleic anhydride polymer, safety evaluation of injection into vas deferens (rat), 217
- "Sunday start" multiphasic oral contraception, ethinyl estradiol + norethindrone acetate (monkey), 321
- Surrogate information, reliability about contraceptive use, smoking, height and weight, 401
- TCu-380A, performance in breastfeeding women, 603
- Terminations,
 - use of ethinyl estradiol + levonorgestrel, 165
 - use of ethinyl estradiol + norethindrone, 165
 - use of levonorgestrel-releasing intracervical device, 187
- Testis,
 - effect of gossypol (rat, hamster), 337
 - effect of intratesticular glycerol injection (monkey), 447
 - entry of gossypol (rat), 569
- Testosterone level, effect of glycerol (monkey), 447
- Tetrahydrocyclopent-b-indole, effect on reproduction (guinea pig), 419
- Toxicity study, evaluation of styrene maleic anhydride injection into vas deferens (rat), 217
- Transdermal delivery,
 - mechanisms, 1
 - steroids, 1
- Transdermal drug delivery, basic requirements, 1
- Transdermal drug delivery system,
 - adhesive diffusion-controlled, 1
 - matrix dispersion-type, 1
 - membrane-moderated, 1
 - microreservoir-type, 1
 - Poroplastic(R) membrane, 1
- Triphasic ethinyl estradiol + gestodene, metabolic effects, 643
- Triphasic ethinyl estradiol + norethindrone acetate, study of "Sunday start" method (monkey), 321

- Triphasic ethinyl oestradiol + levonorgestrel,
 - clinical study, 165
 - effect on blood coagulation, fibrinolysis and platelet function, 369
 - metabolic effects, 21
- Use-effectiveness,
 - ethinyl estradiol + levonorgestrel, 165
 - ethinyl estradiol + norethindrone, 165
- User satisfaction assessment, Norplant(R) implants, 541
- Uterus, effect of anordiol (mouse), 291
- Vaginal contraceptive, soft jelly capsules containing nonoxynol-9, 409
- Vaginal infection, effect on performance of soft jelly capsules containing nonoxynol-9, 409
- Vaginal ring, releasing 3-keto-desogestrel, 653
- Vas deferens, safety evaluation of styrene maleic anhydride injection (rat), 217
- Vascular structures of endometrium, effect of RU486, 103
- Vasectomy,
 - percutaneous electrocoagulation technique, 359
 - standard incision and monopolar diathermy technique, 359
- ZK 98.299 (11 β -(4-dimethyl-aminophenyl)-17 α -hydroxy-17 β -(3-hydroxy propyl)-13 α -methyl-4,9-gonadien-3-one), gonadal and pituitary responses (monkey) 227